The International Society for the Application of Stem Cells presents the schedule of International Cellular therapy certifications for 2024.

Miami, Florida – ISSCA, the International Society for Stem Cell Application and the Educational Division of Global Stem Cells Group, a global leader in cellular therapies and regenerative medicine education, proudly unveils its 2024 schedule for upcoming training dates in multiple countries. In alignment with ISSCA’s mission to extend the benefits of regenerative medicine to all, the organization invites the participation of physicians interested in advancing their expertise in the field.

ISSCA’s commitment to advancing regenerative medicine is exemplified by providing participants with exclusive access to the latest cutting-edge technologies in biologics and regenerative medicine products.

Participants are expected to learn valuable insights into the practical applications of these technologies and acquire knowledge on how regenerative medicine can contribute to addressing contemporary medical challenges, ultimately enhancing patient care.

ISSCA’s comprehensive training program comprises a one-day theoretical segment in which participants learn the fundamentals of cell therapies. It includes discussions on relevant cases and technologies. The practical part encourages participants to apply these therapies on real patients, a portion that lasts from one to two days depending on the ISSCA educational program in the country of the training. Technologies covered include exosomes, umbilical cord stem cells (where permitted), bone marrow and fat stem cells, PRP, and various alternative therapies.

These certifications are meticulously designed for physicians and specialists seeking to expand their knowledge of regenerative medicine and integrate diverse cell therapies into their medical practices.

Key Training Dates for 2024:

  • Cancun, Mexico: February 9, 10, and 11
  • Istanbul, Turkey: February 23 and 24
  • Buenos Aires, Argentina: March 8 & 9
  • Cancun, Mexico: March 22, 23, and 24
  • Brussels, Belgium: March 29 and 30
  • Cancun, Mexico: April 5, 6, and 7
  • Lisbon, Portugal: April 12 and 13
  • Fort Lauderdale, USA: April 19 and 20
  • Santo Domingo, Dominican Republic: May 3 & 4
  • Dubai, UAE: May 17-18
  • Istanbul, Turkey: May 24-25
  • Cancun, Mexico: June 14, 15, and 16
  • Buenos Aires, Argentina: June 28-29
  • Istanbul, Turkey: July 5 and 6
  • Cancun, Mexico: August 9-10-11

For more information on ISSCA certifications and to make reservations, visit https://www.issca.us/, email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

ISSCA is the educational division of Global Stem Cells Group, serving as a multidisciplinary community of scientists and physicians aspiring to treat disease and diminish human suffering through advances in the science, technology, and practice of regenerative medicine. ISSCA serves its members through advances made in the specialty of regenerative medicine.

ISSCA offers certification training in cities around the world, recognizing the importance of standards and certifications in regenerative medicine as a medical specialty. The mission is to promote quality and consistency in regenerative medicine worldwide.

About Global Stem Cells Group:

Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company utilizes its network to provide leadership in regenerative medicine education, research, and patient applications.

GSCG’s mission is to enable physicians to present the benefits of stem cell medicine to patients worldwide. The company also collaborates with policymakers, educators, and regulators to promote regenerative medicine.

Global Stem Cells Group is a publicly traded company under the symbol MSSV. https://finance.yahoo.com/quote/mssv/.

For more information about Global Stem Cells Group, Inc. companies, visit our website www.stemcellsgroup.com or call +1 305 560 5331.

Safe Harbor Statement:

Statements in this news release may be “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Previous Post
Global Stem Cells Group Partners with StemBio to Advance Regenerative Medicine Research and Development
Next Post
International Society for Stem Cell Application (ISSCA) Announces InternationalSymposium on Regenerative Medicine and Cellular Therapies in Cancún, México

Latest posts

Menu